Table 2.

Treatment Outcomes of the Extended Use of HI

Months from HI placement to the implant removal or end of study period; mean±SD, (range)
Total number of implants (N=50)	37.9±13.6 (18–71)
Group A (n=25)a	41.9±12.8 (22–71)
Group B (n=15)	35.9±14.5 (21–71)
Group C (n=2)	25 (21–29)
Group D (n=8)	28.6±11.1 (17–50)
Months from HI placement to last confirmed pubertal suppression (labs/examination), mean±SD, (range)
N=48 implants (group C excluded)	26.3±9.1 (17–65)
Group A (n=25)	25.5±13.4 (17–43)
Group B (n=15)	26±9.8 (19–46)
Group D (n=8)	26±11.7 (17–48)
Implant removal: time from placement, months, mean±SD, (range)
Total cohort (23/50 implants)	32.9±11.5 (17–62)
Group A (9/25)	40.3±12.2 (24–62)
Group B (5/15)	27.6±6.1 (24–36)
Group C (1/2)	29
Group D (8/8)	27.3±12.4 (17–50)

^a Eight subjects later on started GAHT.

GAHT, gender-affirming hormone therapy; HI, histrelin implant.